About: retinalconsultantsaz.com

Posts by retinalconsultantsaz.com:

Pravin U. Dugel MD: Economic Value of Anti–Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States

Karen Mulligan, PhD1,6; Seth A. Seabury, PhD2,6; Pravin U. Dugel, MD3,4; et al Key Points Question  How much economic value do anti–vascular endothelial growth factor (anti-VEGF) treatments generate for patients with wet age-related macular degeneration and society in the United States? Findings  In this economic evaluation study, visual acuity improvement associated with anti-VEGF treatments generated $5.1 billion to $8.2 billion in… Read More »


Dr. Neal Palejwala on AZTV’s Health Matters for Diabetes Awareness Month

Retinal Consultants of Arizona’s Dr. Neal Palejwala was featured on AZTV’s Health Matters segment to discuss diabetes awareness month and the relationship to eye healthcare. Dr. Palejwala discussed the world-class care of the retina practice as well as the Retinal Research Institute – the nation’s leading, independent eye care clinical trial program taking place in… Read More »


Pravin U. Dugel, MD: Conversations in Age-Related Macular Degeneration

Neovascular AMD Pravin U. Dugel, MD What up-and-coming therapies for wet AMD are you most excited about and why? The therapies currently being investigated for neovascular age-related macular degeneration (nvAMD) can be stratified into 3 silos: better short-term efficacy, better long-term efficacy, and increased durability. The majority of drugs in the pipeline have focused on… Read More »


Pravin U. Dugel, MD: Opthea First-in-Human Clinical Data for OPT-302 in wet AMD Published in Leading Ophthalmic Journal

Melbourne, Australia; 29 October 2019 – Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, today announced the publication of positive data from the first-in-human clinical trial of OPT-302, in patients with neovascular (wet) age-related macular degeneration (wet AMD). The successful trial results were published today in Ophthalmology Retina,… Read More »


Pravin U. Dugel, MD: Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

October 08, 2019 01:15 ET | Source: Novartis International AG In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients[1],[2] Beovu demonstrated greater reductions in central subfield thickness (CST, a key indicator of fluid in the… Read More »


Pravin U. Dugel, MD: Touch Ophthalmology Congress Expert Interviews

Professor Pravin U. Dugel, MD Pravin Dugel, Clinical Professor at the Roski Eye Institute, University of Southern California, USA, provides his expert insight into key data presented at EURETINA 2019 and discusses the latest developments in imaging and anti-VEGF agents mean for optimizing outcomes for patients with nAMD. Clinical Spotlight Why retinal fluid is important… Read More »


Pravin U. Dugel, MD: ReNeuron hails “clear signal” from retinitis pigmentosa trials

“Overall, the improvements to date represent a clear signal of efficacy in a patient population where inexorable disease progression is the norm,” the company said Clinical update and conference presentations “Clear efficacy signal” in Phase 2a study of hRPC cell therapy in retinitis pigmentosa ReNeuron Group plc (AIM: RENE), a global leader in the development… Read More »


Retinal Consultants of Arizona partners with American Vision Partners

American Vision Partners (“AVP”), one of the largest and fastest-growing eye care physician practice management organizations in the nation, announced the completion of a strategic partnership with Retinal Consultants of Arizona (“RCA”), the largest retina provider in the Southwest. This partnership creates the fourth largest retina practice in the nation. Retinal Consultants of Arizona will… Read More »


Pravin U. Dugel, MD: Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Board

Eric D. Donnenfeld, M.D., an internationally recognized expert and pioneer in refractive, cornea and cataract surgery  Ramin Tadayoni, M.D., Ph.D., renowned professor and ophthalmologist in the diagnosis and treatment of retinal diseases, retinovitreal surgery and ophthalmic imaging  Lausanne, Switzerland, September 17, 2019 – Oculis S.A., a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments for… Read More »


Pravin U. Dugel, MD: Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME

Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME Immediate onset of action – starting from Day 1 with increasing average improvement in Best Corrected Visual Acuity (BCVA) of up to 7.5 letters at Day 14 following a single injection of THR-149. Prolonged durability… Read More »